What is it about?

We built a model for lung cancer diagnosis based on the blood biomarkers progastrin-releasing peptide (ProGRP), carcinoembryonic antigen (CEA), squamous cell carcinoma antigen (SCC), and cytokeratin 19 fragment (CYFRA21-1). In the study, we examined whether modification of the model to include relevant clinical information, risk factors, and low-dose chest computed tomography screening would improve the performance of the biomarker panel in large cohorts of Chinese adults.

Featured Image

Why is it important?

Both the patient risk model and the nodule risk model, developed for the early diagnosis of lung cancer, demonstrated excellent discrimination, allowing for the stratification of patients with different levels of lung cancer risk. These new models are applicable in high-risk Chinese populations.

Perspectives

This study is the first multi-center study launched among Chinese Alliance Against Lung Cancer. It is very appreciated for all the patients, researchers, professors and collaborators in this study. In the study, we developed two models for stratification the risk of developing lung cancer and the malignancy of pulmonary nodule found in the CT scan. Also we found by training and validating in the local dataset, the model would be improved on the efficacy comparing with the external risk model. Hopefully by recruiting more cases and validation in a larger cohort, the two panels could improve early diagnosis of lung cancer in Chinese high risk population.

Dr. DAWEI YANG
Zhongshan Hospital Fudan University

Read the Original

This page is a summary of: Probability of cancer in high-risk patients predicted by the protein-based lung cancer biomarker panel in China: LCBP study, Cancer, September 2017, Wiley,
DOI: 10.1002/cncr.31020.
You can read the full text:

Read

Resources

Contributors

The following have contributed to this page